CLARITIN HIVES RELIEF REDITAB Drug Patent Profile

When do Claritin Hives Relief Reditab patents expire, and when can generic versions of Claritin Hives Relief Reditab launch?

Claritin Hives Relief Reditab is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN HIVES RELIEF REDITAB is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin Hives Relief Reditab

A generic version of CLARITIN HIVES RELIEF REDITAB was approved as loratadine by PLD ACQUISITIONS LLC on January 21^st, 2003.

Summary for CLARITIN HIVES RELIEF REDITAB

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	148
Patent Applications:	2,849
DailyMed Link:	CLARITIN HIVES RELIEF REDITAB at DailyMed

US Patents and Regulatory Information for CLARITIN HIVES RELIEF REDITAB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN HIVES RELIEF REDITAB	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-003	Nov 19, 2003		OTC	Yes	Yes

International Patents for CLARITIN HIVES RELIEF REDITAB

See the table below for patents covering CLARITIN HIVES RELIEF REDITAB around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	55797	Fluoro substituted benzocycloheptapyridine compounds compositions and methods of use as antihistaminic compounds
Hungary	194864	PROCESS FOR PRODUCTION OF 8-CHLOR-6,11-DIHYDRO-11-(4-PIPERIDILIDENE)-5H-BENZO (5,6)-CYCLO-HEPTA (1,2-B) PYRIDINE AND ITS SALTS
Spain	554898
Australia	5737486
Argentina	241463	PROCEDIMIENTO PARA PREPARAR AZA DERIVADOS DE PIPERILIDEN CICLOHEPTENOS, Y PROCEDIMIENTO PARA PREPARAR COMPOSICIONES FARMACEUTICAS UTILES. (PROCESS FOR PREPARING PIPERIDYLIDENE DIHYDRODIBENZO(A,D)CYCLOHEPTENES AND AZA DERIVATIVES THEREOF, COMPOUNDS OBTAINED BY SUCH PROCESS AND THE USE OF SUCH COMPOUNDS FOR PREPARING USEFUL PHARMACEUTICAL COMPOSITIONS)

Supplementary Protection Certificates for CLARITIN HIVES RELIEF REDITAB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

CLARITIN HIVES RELIEF REDITAB Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Claritin Hives Relief Reditab

Introduction to Claritin Hives Relief Reditab

Claritin Hives Relief Reditab, a formulation of the antihistamine loratadine, is widely used to alleviate symptoms of hay fever, hives, and other allergic reactions. This medication is part of the broader Claritin market, which is experiencing significant growth driven by various market dynamics.

Market Size and Forecast

The Claritin market, which includes Claritin Hives Relief Reditab, was valued at USD 0.16 billion in 2023 and is projected to reach USD 0.26 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.67% during the forecast period of 2024-2031[1][4].

Global Market Drivers

Several factors are driving the growth of the Claritin market:

Product Innovation

Continuous research and development have led to novel formulations, including extended-release variants and combination medicines. These innovations enhance convenience and efficacy, making them more appealing to consumers[1].

Alterations in Lifestyle Factors

Urbanization and increased exposure to allergens such as pollen, dust mites, and pet dander have resulted in a higher demand for allergy treatments. This shift in lifestyle factors contributes significantly to the market growth[1].

Seasonal Demand

Seasonal allergies, particularly during spring and autumn, drive up the demand for allergy relief medications like Claritin. This periodic increase in demand is a key driver of the market[1].

Promotions and Marketing

Effective marketing strategies, including commercials and promotions, play a crucial role in enhancing brand awareness and stimulating sales. Strong marketing efforts by major players like Bayer AG, Sanofi, Pfizer, Johnson & Johnson, and Merck help in maintaining market momentum[1].

Global Expansion

The expansion of Claritin into new markets and regions is expanding its consumer base and potential revenue. This global reach is vital for sustained growth[1].

Market Challenges

Despite the growth drivers, the Claritin market faces several challenges:

Competition from Generic Brands

The presence of generic loratadine products at lower prices can constrain the market share of branded Claritin, impacting profitability[1].

Market Saturation

The presence of numerous established antihistamine medicines can lead to market saturation, complicating Claritin’s efforts to sustain growth[1].

Adverse Effects and Consumer Reservations

Some consumers may be reluctant to use antihistamines due to possible side effects, such as drowsiness, although Claritin is known to be non-drowsy. This consumer skepticism can hinder widespread acceptance[1][5].

Regulatory Challenges

Changes in legislation or constraints on advertising and marketing can influence the promotion and sale of Claritin products[1].

Economic Factors

Economic recessions or fluctuations can impact consumer expenditure on healthcare products, including allergy medications[1].

Changes in Consumer Preferences

Increasing trends towards natural and holistic health treatments may prompt customers to seek alternatives to traditional drugs like Claritin[1].

Geographical Segmentation

The Claritin market is segmented geographically into several key regions:

North America

North America, particularly the United States and Canada, has significant market penetration due to strong brand recognition and high prevalence of allergic conditions. Effective marketing strategies and consumer trust drive the market in this region[1].

Europe

Europe, with countries like Germany and the UK, shows substantial demand influenced by rising pollen levels and increased awareness about allergic rhinitis[1].

Asia-Pacific

The Asia-Pacific region is emerging as a significant market driven by a growing population, urbanization, and higher disposable income, contributing to increased healthcare spending and awareness of allergy-related products[1].

Latin America, Middle East, and Africa

These regions present unique challenges, such as varying healthcare infrastructure, but also opportunities due to increasing demand for healthcare solutions among the growing population[1].

Distribution Channels

The distribution of Claritin is facilitated through various channels:

Online Retail

Online retail has emerged as a dynamic sub-segment, experiencing significant growth due to increasing digital penetration and the convenience of home delivery. This channel appeals particularly to tech-savvy consumers and those who prefer privacy in their purchasing[1].

Health Stores

Health stores, which focus on natural and over-the-counter remedies, cater to health-conscious consumers seeking specialized products and personalized service. These stores enrich the overall market landscape by providing diverse accessibility[1].

Side Effects and Precautions

While Claritin is generally well-tolerated, it can cause some side effects:

Common Side Effects

Headache, dizziness, dry mouth, and fatigue are among the more common side effects. Less common side effects include dysmenorrhea, dyspepsia, myalgia, pharyngitis, and somnolence[2][5].

Precautions

Consumers should be aware of potential drowsiness, although Claritin is marketed as non-drowsy. It is also important to consult a doctor if symptoms do not improve or worsen over time[2][5].

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the healthcare sector, including the loratadine market. Studies have explored the effectiveness of loratadine in treating COVID-19 symptoms, which has influenced market dynamics. However, the pandemic also highlighted the importance of continuous development in antihistamine drugs, driving market growth[3].

Key Players

Major players in the Claritin market include:

• Bayer AG
• Sanofi
• Pfizer
• Johnson & Johnson
• Merck

These companies play a crucial role in driving innovation, marketing, and distribution efforts that shape the market[1].

Conclusion

The Claritin Hives Relief Reditab market is poised for significant growth, driven by product innovation, lifestyle changes, seasonal demand, and effective marketing. However, it must navigate challenges such as competition from generic brands, market saturation, and regulatory hurdles.

Key Takeaways

• The Claritin market is projected to grow from USD 0.16 billion in 2023 to USD 0.26 billion by 2031 at a CAGR of 5.67%.
• Key drivers include product innovation, lifestyle changes, and effective marketing.
• The market faces challenges from generic brands, market saturation, and consumer preferences for natural treatments.
• Geographical segmentation highlights North America, Europe, and the Asia-Pacific as significant markets.
• Distribution channels include online retail and health stores.
• Side effects and precautions are important considerations for consumers.

Frequently Asked Questions

1. What is the projected market size of Claritin by 2031?

The Claritin market is expected to reach USD 0.26 billion by 2031[1][4].

2. What is the CAGR of the Claritin market from 2024 to 2031?

The Claritin market is expected to exhibit a CAGR of 5.67% during the forecast period[1][4].

3. What are the main drivers of the Claritin market?

The main drivers include product innovation, alterations in lifestyle factors, seasonal demand, and effective marketing and promotions[1].

4. Which regions are significant for the Claritin market?

North America, Europe, and the Asia-Pacific region are significant markets for Claritin, with each region driven by different factors such as brand recognition, urbanization, and healthcare spending[1].

5. What are some common side effects of Claritin?

Common side effects include headache, dizziness, dry mouth, and fatigue. Less common side effects include dysmenorrhea, dyspepsia, myalgia, pharyngitis, and somnolence[2][5].

Sources:

1. Verified Market Research - Claritin Market Size, Share, Growth, Trends & Forecast
2. Mayo Clinic - Desloratadine (oral route)
3. Mordor Intelligence - Loratadine Market - Size, Analysis, Industry Share & Growth
4. Business Research Insights - Claritin Market Size, Share Growth and Forecast Till 2032
5. Mayo Clinic - Loratadine (oral route)